EP Patent

EP3363807B1 — Pharmaceutical composition comprising crystalline (2s,3r,4s,5s,6r)-2-[4-chloro-3-(4-ethoxy-benzyl)-phenyl]-6-hydroxymethyl-2-methoxy-tetrahydro-pyran-3,4,5-triol (s)-propylene glycol solvate

Assigned to AstraZeneca AB · Expires 2019-11-13 · 7y expired

What this patent protects

Patent listed against Farxiga.

Drugs covered by this patent

Patent Metadata

Patent number
EP3363807B1
Jurisdiction
EP
Classification
—
Expires
2019-11-13
Drug substance claim
No
Drug product claim
No
Assignee
AstraZeneca AB
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.